State of Alaska Department of Revenue Grows Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

State of Alaska Department of Revenue raised its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGOGet Rating) by 10.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,933 shares of the company’s stock after buying an additional 4,633 shares during the quarter. State of Alaska Department of Revenue’s holdings in Organogenesis were worth $158,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Louisiana State Employees Retirement System purchased a new position in shares of Organogenesis in the 3rd quarter worth approximately $110,000. Federated Hermes Inc. boosted its holdings in shares of Organogenesis by 151.5% in the 2nd quarter. Federated Hermes Inc. now owns 2,592,012 shares of the company’s stock worth $12,649,000 after purchasing an additional 1,561,269 shares during the period. Legal & General Group Plc boosted its holdings in shares of Organogenesis by 4.5% in the 2nd quarter. Legal & General Group Plc now owns 148,022 shares of the company’s stock worth $723,000 after purchasing an additional 6,374 shares during the period. Walleye Capital LLC purchased a new position in shares of Organogenesis in the 2nd quarter worth approximately $75,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Organogenesis by 13.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,048,311 shares of the company’s stock worth $5,116,000 after purchasing an additional 124,825 shares during the period. Hedge funds and other institutional investors own 47.03% of the company’s stock.

Organogenesis Price Performance

ORGO opened at $2.59 on Monday. The business has a fifty day moving average of $2.70 and a 200 day moving average of $3.65. Organogenesis Holdings Inc. has a 52-week low of $2.23 and a 52-week high of $9.27. The company has a quick ratio of 2.31, a current ratio of 2.58 and a debt-to-equity ratio of 0.26. The stock has a market cap of $339.07 million, a P/E ratio of 5.63 and a beta of 1.60.

Organogenesis (NASDAQ:ORGOGet Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). Organogenesis had a net margin of 13.06% and a return on equity of 28.74%. The business had revenue of $116.86 million for the quarter, compared to analysts’ expectations of $121.40 million. As a group, sell-side analysts anticipate that Organogenesis Holdings Inc. will post 0.13 EPS for the current year.

Analysts Set New Price Targets

Separately, BTIG Research cut Organogenesis from a “buy” rating to a “neutral” rating in a report on Thursday, November 10th.

Organogenesis Company Profile

(Get Rating)

Organogenesis Holdings Inc, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved.

Featured Articles

Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis Holdings Inc. (NASDAQ:ORGOGet Rating).

Institutional Ownership by Quarter for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.